Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC3 | Q13507 | 3/20 | 0.39 |
| ▸ | TRPC6 | Q9Y210 | 3/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 6/20 | 0.32 |
| ▸ | OGA | O60502 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979827 | 0.90 | TRPC3 (0.37) | TRPC3TRPC6MAP3K14OGAPTGDR2 | |
| SCHEMBL978328 | 0.87 | TRPC3 (0.35) | TRPC3TRPC6MAP3K14PTGDR2SCD5 | |
| SCHEMBL977808 | 0.87 | PTGDR2 (0.34) | NPC1RAB9APTGDR2 | |
| SCHEMBL980145 | 0.86 | PTGDR2 (0.35) | PTGDR2SMN1; SMN2 | |
| SCHEMBL977386 | 0.85 | PTGDR2 (0.37) | PTGDR2 | |
| SCHEMBL976590 | 0.82 | TRPC3 (0.45) | TRPC3TRPC6DYRK1ANPC1RAB9A | |
| SCHEMBL978006 | 0.82 | FNTA (0.36) | PTGDR2 | |
| SCHEMBL977762 | 0.76 | PTGDR2 (0.34) | PTGDR2 | |
| SCHEMBL980003 | 0.76 | MAPT (0.38) | NPC1RAB9AOPRK1SMN1; SMN2LMNA | |
| SCHEMBL978816 | 0.76 | PTGDR2 (0.35) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440830-B2 | Tetrahydro-fused pyridines as histone deacetylase inhibitors | 4SC AG (DE) | 2013-05-14 | — | — | US | disclosed |
| EP-2197552-B1 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2197552-A2 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009037001-A2 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC3 | TRPC3 4653/4885TRPC6 4552/4885DYRK1A 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.